Avenue Therapeutics (ATXI) Misses Q2 EPS by 39c
Avenue Therapeutics (NASDAQ: ATXI) reported Q2 EPS of ($0.52), $0.39 worse than the analyst estimate of ($0.13).
For earnings history and earnings-related data on Avenue Therapeutics (ATXI) click here.
Avenue Therapeutics (NASDAQ: ATXI) reported Q2 EPS of ($0.52), $0.39 worse than the analyst estimate of ($0.13).
For earnings history and earnings-related data on Avenue Therapeutics (ATXI) click here.